NBIX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NBIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Neurocrine Biosciences's tax expense for the months ended in Dec. 2024 was $60 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2024 was $145 Mil.
The historical data trend for Neurocrine Biosciences's Tax Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Tax Expense | Get a 7-Day Free Trial |
![]() |
![]() |
-300.60 | 11.80 | 59.40 | 82.40 | 144.70 |
Neurocrine Biosciences Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Tax Expense | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
50.50 | -8.90 | 33.60 | 60.50 | 59.50 |
Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.
Tax Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $145 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (NAS:NBIX) Tax Expense Explanation
In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.
Thank you for viewing the detailed overview of Neurocrine Biosciences's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Eiry Roberts | officer: Chief Medical Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130 |
Stephen A Sherwin | director | C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080 |
Ingrid Delaet | officer: Chief Regulatory Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Jude Onyia | officer: Chief Scientific Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
David W. Boyer | officer: Chief Corp. Affairs Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Matt Abernethy | officer: Chief Financial Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121 |
Eric Benevich | officer: Chief Commerical Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130 |
Kyle Gano | officer: Chief Business Dev Officer | NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Darin Lippoldt | officer: Chief Legal Officer | C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Kevin Charles Gorman | officer: Sr VP, Business Development | 12790 EL CAMINO REAL, SAN DIEGO CA 92130 |
Julie Cooke | officer: Chief Human Resources Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
William H Rastetter | director | 9885 TOWNE CENTRE DR., SAN DIEGO CA 92121 |
Gary A Lyons | director, officer: President and CEO | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Leslie V Norwalk | director | C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130 |
Richard F Pops | director | 10555 SCIENCE CENTER DR, SAN DIEGO CA 92121 |
From GuruFocus
By GuruFocus News • 01-21-2025
By PRNewswire • 12-20-2024
By PRNewswire • 01-08-2025
By GuruFocus News • 01-23-2025
By GuruFocus News • 02-07-2025
By GuruFocus News • 02-06-2025
By GuruFocus News • 01-06-2025
By GuruFocus News • 02-07-2025
By GuruFocus News • 12-20-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.